approval
saveTRILEPTAL (OXCARBAZEPINE) — FDA approval
community read0 votes
Sponsor: NOVARTIS. Form: SUSPENSION. Route: ORAL
view source ↗Data sources
last refreshed 5mo ago
Found something off?
drug timeline · 8
- approvalOXCARBAZEPINE — FDA approvalMar 2, 2026 · 216d ago
- approvalTRILEPTAL (OXCARBAZEPINE) — FDA approvalSep 23, 2025 · 376d ago
- approvalTRILEPTAL (OXCARBAZEPINE) — FDA approvalSep 23, 2025 · 376d ago
- approvalTRILEPTAL (OXCARBAZEPINE) — FDA approvalSep 4, 2024 · 760d ago
- approvalTRILEPTAL (OXCARBAZEPINE) — FDA approvalJan 4, 2019 · 2830d ago
- approvalTRILEPTAL (OXCARBAZEPINE) — FDA approvalJan 4, 2019 · 2830d ago
- approvalTRILEPTAL (OXCARBAZEPINE) — FDA approvalMar 22, 2018 · 3118d ago
- approvalTRILEPTAL (OXCARBAZEPINE) — FDA approvalMar 22, 2018 · 3118d ago
same company · ±60 days · 6
- approvalOXCARBAZEPINE: TRILEPTAL (OXCARBAZEPINE) — FDA approvalSep 4, 2024
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalAug 16, 2024
- approvalCOSENTYX (SECUKINUMAB) — FDA approvalAug 16, 2024
- approvalSpexotras: MEKINIST (TRAMETINIB DIMETHYL SULFOXIDE) — FDA approvalOct 1, 2024
- approvalSpexotras: MEKINIST (TRAMETINIB) — FDA approvalOct 1, 2024
- approvalasciminib hydrochloride: SCEMBLIX (ASCIMINIB HYDROCHLORIDE) — FDA approvalAug 7, 2024
comments(0)
5-min edit window · permanent after that